Knowing stock market today at a glance

Travere Therapeutics Soars 10.91% on Analyst Upgrades

Mover TrackerFriday, Apr 18, 2025 5:09 am ET

1min read

On April 18, 2025, travere therapeutics saw a significant rise of 10.91% in pre-market trading, indicating strong investor interest and potential market momentum.

Travere Therapeutics has been the subject of several recent research reports. Analysts have given the company a "Moderate Buy" rating with an average target price of $32.08. evercore ISI upped their target price on Travere Therapeutics from $33.00 to $45.00 and gave the company an “outperform” rating. Scotiabank restated an “outperform” rating on shares of travere therapeutics. Cantor Fitzgerald reiterated an “overweight” rating on shares of Travere Therapeutics. Citigroup upped their price target on shares of Travere Therapeutics from $31.00 to $35.00 and gave the stock a “buy” rating. JPMorgan Chase & Co. boosted their target price on shares of Travere Therapeutics from $42.00 to $44.00 and gave the company an “overweight” rating.

Several institutional investors have recently bought and sold shares of the company. Franklin Resources Inc. bought a new position in shares of Travere Therapeutics during the fourth quarter. Geode Capital Management LLC boosted its holdings in Travere Therapeutics by 3.9% in the third quarter. Diversified Trust Co grew its position in shares of Travere Therapeutics by 27.5% during the fourth quarter. R Squared Ltd acquired a new stake in Travere Therapeutics during the fourth quarter. Baader Bank Aktiengesellschaft bought a new position in Travere Therapeutics in the fourth quarter.

Travere Therapeutics, Inc. is a biopharmaceutical company that identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.

Disclaimer: the above is a summary showing certain market information. AInvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.